Investment
Features
FeesSafety
Academy
More
Pluang+

Compare VanEck Australian Floating Rate ETF (FLOT) vs GSK plc (GSK) Price & Performance

VanEck Australian Floating Rate ETFTrade

Price performance (Past 24H)

Key statistics

VanEck Australian Floating Rate ETF vs GSK plc — how do they compare? VanEck Australian Floating Rate ETF trades at $50.94, while GSK plc trades at $51.15 (market cap $102.60B). The key difference: GSK plc pays a 3.57% dividend while VanEck Australian Floating Rate ETF pays none. Which is the better fit depends on your goals.

FLOTGSK
Sector
Sector/ThematicHealth
52-Week High
$51.09$61.18
52-Week Low
$50.72$38.22
Market Cap
$102.60B
Enterprise Value
$123.04B
Dividend Yield
3.57%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

VanEck Australian Floating Rate ETF

FLOT trades at $50.93 with minimal daily movement (+0.02%). Technical indicators show a bearish trend with moving averages signaling sell pressure, though oscillators are neutral. The ETF maintains consistent dividend payments with recent distributions of $0.17-$0.18. Market focus remains on Federal Reserve policy decisions and their impact on floating rate bonds amid persistent inflation concerns.

FLOT offers exposure to high-quality floating rate bonds with a 4.0% SEC yield, positioned as a conservative income vehicle. The ETF benefits from potential Fed rate hikes but faces headwinds from inflation volatility and Treasury yield fluctuations. Current technical weakness suggests cautious near-term positioning despite the defensive characteristics of floating rate securities.

GSK plc

GSK trades at $50.27, down 3.62% today, with a bearish technical signal but strong fundamentals including a P/E of 16.02 and net income margin of 14.52%. Recent quarters show earnings beats, and the company announced a $2.52 billion cost-saving plan to boost its drug pipeline. Cash flow from operations remains robust at $7.74 billion for 2025.

The outlook is mixed: analyst consensus leans hold (55.18%) amid valuation concerns, but revenue growth and pipeline investments support long-term potential. Key risks include competitive pressures and regulatory uncertainty, as highlighted by recent news on vaccine policies. The stock offers a dividend yield with payments scheduled through 2026.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About VanEck Australian Floating Rate ETF

FLOT provides exposure to a diversified portfolio of Australian dollar-denominated floating rate notes. It tracks the Bloomberg AusBond Credit FRN 0+ Yr Index, focusing on high-quality, investment-grade bonds from top Australian banks and financial institutions.

Read more on FLOT

About GSK plc

In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.

Read more on GSK